Pub Date : 2020-01-01DOI: 10.35248/2155-9570.20.11.858
Alej, ra Gonzalez-Calle, V. Jeganathan, M. Humayun, J. Weil
Retinal prostheses provide blind patients with the ability to detect motion and locate large objects. Future implants will require smaller electrodes to improve resolution, but increased charge density may result, creating a safety concern. We developed a novel in vivo method to study the effects of electrical stimulation in the retina using real time Optical Coherence Tomography (OCT) imaging combined with micropositioning a stimulating electrode. We observed that electrical stimulation settings with both pulse rates at and greater than 100 Hz as well as charge density 1.22 mC/cm2 and above resulted in retinal thickening within minutes of stimulation, that affected several retinal layers. We showed with statistical significance that the median difference between the retinal thickness before and after stimulation was different from zero. In summary, both high rate and high charge density were required to create retinal thickening. The stimulus levels at which thickening was noted in our study were significantly higher than the parameters currently used in humans.
{"title":"Effects of Electrical Stimulation on Retinal Morphology as Seen with Optical Coherence Tomography","authors":"Alej, ra Gonzalez-Calle, V. Jeganathan, M. Humayun, J. Weil","doi":"10.35248/2155-9570.20.11.858","DOIUrl":"https://doi.org/10.35248/2155-9570.20.11.858","url":null,"abstract":"Retinal prostheses provide blind patients with the ability to detect motion and locate large objects. Future implants will require smaller electrodes to improve resolution, but increased charge density may result, creating a safety concern. We developed a novel in vivo method to study the effects of electrical stimulation in the retina using real time Optical Coherence Tomography (OCT) imaging combined with micropositioning a stimulating electrode. We observed that electrical stimulation settings with both pulse rates at and greater than 100 Hz as well as charge density 1.22 mC/cm2 and above resulted in retinal thickening within minutes of stimulation, that affected several retinal layers. We showed with statistical significance that the median difference between the retinal thickness before and after stimulation was different from zero. In summary, both high rate and high charge density were required to create retinal thickening. The stimulus levels at which thickening was noted in our study were significantly higher than the parameters currently used in humans.","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"1 1","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82730449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.35248/2155-9570.20.11.831
Elien Gyrr, Bakayoko Seydou, D. Adam, Théra Jp
Introduction: Symblepharon is a lesion on the ocular surface associated or not with ocular adnexa damage. Symblepharon is characterized by the formation of an adhesion between the palpebral conjunctiva and the bulbary conjunctiva. There are many causes of symblepharon, among which toxic epidermal necrolysis is the most well-known and documented due to the extreme severity of ocular damage. Hence the purpose of this study is to describe the epidemiological-clinical profile of the symbpharon during the toxic epidermal necrosis for adequate and appropriate management. Methodology: This was a cross-sectional study, lasting 24 months from 18 March 2018 to 17 March 2020 at CHUIOTA. All patients who consented and had the symblepharon regardless of sex and age were compiled in a nonprobability sample. Results: During the 2 years, 11 patients were collected. There were 4 Men and 7 Women. The average age of our patients was 36.81 14.60 years, the age extremes ranged from 7 years old to 65 years old. The association of Nevirapine and Cotrimoxazole was frequently incriminated in 36.4% of our patients. More than half of the symblepharon were anterior (55% of the cases). Discussion: The bilaterality of ocular damage would be related on the one hand to the immunological mechanisms of toxic epidermal necrolysis, and the association of Nevirapine with Cotrimoxazole on the other. Conclusion: A rare disease, toxic epidermal necrolysis often leads to severe ocular complications.
{"title":"Epidemio-Clinical Profile of the Symbpharon during Toxic Epidermal Necrolysis (TEN) at the Institute of African Tropical Ophthalmology-Teaching Hospital","authors":"Elien Gyrr, Bakayoko Seydou, D. Adam, Théra Jp","doi":"10.35248/2155-9570.20.11.831","DOIUrl":"https://doi.org/10.35248/2155-9570.20.11.831","url":null,"abstract":"Introduction: Symblepharon is a lesion on the ocular surface associated or not with ocular adnexa damage. Symblepharon is characterized by the formation of an adhesion between the palpebral conjunctiva and the bulbary conjunctiva. There are many causes of symblepharon, among which toxic epidermal necrolysis is the most well-known and documented due to the extreme severity of ocular damage. Hence the purpose of this study is to describe the epidemiological-clinical profile of the symbpharon during the toxic epidermal necrosis for adequate and appropriate management. Methodology: This was a cross-sectional study, lasting 24 months from 18 March 2018 to 17 March 2020 at CHUIOTA. All patients who consented and had the symblepharon regardless of sex and age were compiled in a nonprobability sample. Results: During the 2 years, 11 patients were collected. There were 4 Men and 7 Women. The average age of our patients was 36.81 14.60 years, the age extremes ranged from 7 years old to 65 years old. The association of Nevirapine and Cotrimoxazole was frequently incriminated in 36.4% of our patients. More than half of the symblepharon were anterior (55% of the cases). Discussion: The bilaterality of ocular damage would be related on the one hand to the immunological mechanisms of toxic epidermal necrolysis, and the association of Nevirapine with Cotrimoxazole on the other. Conclusion: A rare disease, toxic epidermal necrolysis often leads to severe ocular complications.","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"33 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77041262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.35248/2155-9570.20.11.824
Kawtar Zaoui, I. Tarib, R. Messaoudi, K. Reda
Rare idiopathic clinical entity, described by Chang et al. in 1995 for the first time, then in 2007 Samuel et al. published a classification according to the progressive stages of the disease. It is a condition which generally affects young women aged 30 to 40. Its evolution is variable and can be serious. Several therapeutic modalities are possible.
{"title":"An Atypical Idiopathic Retinal Vasculitis, Aneurysms and Neuroretinitis IRVAN: Case Report","authors":"Kawtar Zaoui, I. Tarib, R. Messaoudi, K. Reda","doi":"10.35248/2155-9570.20.11.824","DOIUrl":"https://doi.org/10.35248/2155-9570.20.11.824","url":null,"abstract":"Rare idiopathic clinical entity, described by Chang et al. in 1995 for the first time, then in 2007 Samuel et al. published a classification according to the progressive stages of the disease. It is a condition which generally affects young women aged 30 to 40. Its evolution is variable and can be serious. Several therapeutic modalities are possible.","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"7 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87770933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.35248/2155-9570.20.11.827
S. Jabbehdari, Jonathan H. Lin, Yangyan Sun
{"title":"Congenital Bilateral Glaucoma in a Patient with Neurofibromatosis Type I","authors":"S. Jabbehdari, Jonathan H. Lin, Yangyan Sun","doi":"10.35248/2155-9570.20.11.827","DOIUrl":"https://doi.org/10.35248/2155-9570.20.11.827","url":null,"abstract":"","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"195 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86827786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.35248/2155-9570.20.11.848
E. Klug, Marika Chachanidze, Abraham Nirappel, N. Hall, T. C. Chang, David Sol -Del Valle
Objective: There is controversy surrounding the next best step in treating plateau iris syndrome (PIS) patients with persistent angle dysfunction despite a patent laser peripheral iridotomy (LPI). The aim of this study was to examine the effectiveness of argon laser peripheral iridoplasty (ALPI) in PIS patients with a patent LPI. Methods: Retrospective review of medical records in consecutive patients that underwent ALPI to treat persistently narrow angles due to underlying PIS after a patent LPI. Patients in whom angle configuration could not be ascertained by review of medical records, those with less than 12 months follow-up at our institution, or those younger than 18 years of age were excluded. Kaplan-Meier survival analysis was used to determine treatment survival time. Paired t-tests were used to compare intraocular pressure (IOP), number of glaucoma medications, and bestcorrected visual acuity (BCVA) 12 months post-ALPI and at the last follow-up visit. Results: Fifty-one eyes of 51 patients were included in the analysis. The median survival time for a successful ALPI procedure was 1023 days (34.1 months). The majority of failure events were attributed to cataract extraction to open a persistently narrow angle, performed at approximately 934 (± 694) days (31.1 months) after ALPI. No changes in IOP, number of glaucoma medications, or BCVA from baseline were observed after 12 months or at last follow-up. Conclusion: ALPI is a potentially effective treatment for PIS following LPI. While angle dysfunction may re-emerge over time, ALPI can potentially delay the need for lensectomy in patients without visually significant cataracts.
{"title":"Effectiveness of Argon Laser Peripheral Iridoplasty in Plateau Iris Syndrome Patients after Laser Peripheral Iridotomy","authors":"E. Klug, Marika Chachanidze, Abraham Nirappel, N. Hall, T. C. Chang, David Sol -Del Valle","doi":"10.35248/2155-9570.20.11.848","DOIUrl":"https://doi.org/10.35248/2155-9570.20.11.848","url":null,"abstract":"Objective: There is controversy surrounding the next best step in treating plateau iris syndrome (PIS) patients with persistent angle dysfunction despite a patent laser peripheral iridotomy (LPI). The aim of this study was to examine the effectiveness of argon laser peripheral iridoplasty (ALPI) in PIS patients with a patent LPI. Methods: Retrospective review of medical records in consecutive patients that underwent ALPI to treat persistently narrow angles due to underlying PIS after a patent LPI. Patients in whom angle configuration could not be ascertained by review of medical records, those with less than 12 months follow-up at our institution, or those younger than 18 years of age were excluded. Kaplan-Meier survival analysis was used to determine treatment survival time. Paired t-tests were used to compare intraocular pressure (IOP), number of glaucoma medications, and bestcorrected visual acuity (BCVA) 12 months post-ALPI and at the last follow-up visit. Results: Fifty-one eyes of 51 patients were included in the analysis. The median survival time for a successful ALPI procedure was 1023 days (34.1 months). The majority of failure events were attributed to cataract extraction to open a persistently narrow angle, performed at approximately 934 (± 694) days (31.1 months) after ALPI. No changes in IOP, number of glaucoma medications, or BCVA from baseline were observed after 12 months or at last follow-up. Conclusion: ALPI is a potentially effective treatment for PIS following LPI. While angle dysfunction may re-emerge over time, ALPI can potentially delay the need for lensectomy in patients without visually significant cataracts.","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"29 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83541274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.35248/2155-9570.21.11.853
H. Torabi, Seyed-Hashem Daryabari
This report describe the anatomical and visual outcomes of concurrent pars planavitrectomy (PPV) and Descemet stripping automated endothelial keratoplasty (DSAEK) for the management of a case with pseudophakic bullous keratopathy (PBK) and intraocular lens (IOL) dislocation following complicated phacoemulsification surgery. A 72-year-old woman was referred to our clinic 7 days after complicated phacoemulsification surgery. Severe corneal edema and IOL dislocation into the vitreous cavity was noticed on examination. After 2 months of conservative treatment, corneal edema remained persistent, so concurrent 23-gauge PPV, DSAEK and iris supported IOL implantation were performed in the single surgical procedure. One year after operation, the cornea was clear, retina was attached and best corrected visual acuity was 20/32. This report showed that concurrent PPV and DSAEK may be safe and effective option for the management of severely complicated Phacoemulsification surgery with PBK and IOL dislocation into the vitreous cavity.
{"title":"Concurrent Pars Plana Vitrectomy and DSAEK to Manage Pseudophakic Bullous Keratopathy and Intraocular Lens Dislocation: A Case Report","authors":"H. Torabi, Seyed-Hashem Daryabari","doi":"10.35248/2155-9570.21.11.853","DOIUrl":"https://doi.org/10.35248/2155-9570.21.11.853","url":null,"abstract":"This report describe the anatomical and visual outcomes of concurrent pars planavitrectomy (PPV) and Descemet stripping automated endothelial keratoplasty (DSAEK) for the management of a case with pseudophakic bullous keratopathy (PBK) and intraocular lens (IOL) dislocation following complicated phacoemulsification surgery. A 72-year-old woman was referred to our clinic 7 days after complicated phacoemulsification surgery. Severe corneal edema and IOL dislocation into the vitreous cavity was noticed on examination. After 2 months of conservative treatment, corneal edema remained persistent, so concurrent 23-gauge PPV, DSAEK and iris supported IOL implantation were performed in the single surgical procedure. One year after operation, the cornea was clear, retina was attached and best corrected visual acuity was 20/32. This report showed that concurrent PPV and DSAEK may be safe and effective option for the management of severely complicated Phacoemulsification surgery with PBK and IOL dislocation into the vitreous cavity.","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"22 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90865374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.35248/2155-9570.20.11.861
Beena Alam
Retinitis Pigmentosa, abbreviated as RP, is a global eye retina disorder. In this mini review paper, my focus just only its basic causes, prevalence, symptom, and factors and also discuss retina syndrome related to this disease, to provide a basic knowledge for beginners and readers to understand about what is retinitis pigmentosa disease.
{"title":"Retinitis Pigmentosa (RP) at a Glance","authors":"Beena Alam","doi":"10.35248/2155-9570.20.11.861","DOIUrl":"https://doi.org/10.35248/2155-9570.20.11.861","url":null,"abstract":"Retinitis Pigmentosa, abbreviated as RP, is a global eye retina disorder. In this mini review paper, my focus just only its basic causes, prevalence, symptom, and factors and also discuss retina syndrome related to this disease, to provide a basic knowledge for beginners and readers to understand about what is retinitis pigmentosa disease.","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"33 8 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77459467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.35248/2155-9570.20.11.845
Ze-Peng Xu, Song-Tiao Li, Kun-Meng Li, Ruoxi Geng, Haike Guo, Hong-Yang Zhang, Haiyin Jin, AN Mei-Xia, N. Tian
Objective: To evaluate the accuracy of three calculation formulas of intraocular lens (IOL) on the refractive state of cataract patients with high myopia after cataract surgery, to study the influence of three formulas on axial length (AL), and to verify the advantage of Olsen formula over SRK/T and Haigis formula in predicting postoperative refraction in patients with high myopia and cataract, so as to provide a basis for selecting the degree of IOL in cataract patients with high myopia, so as to provide a basis for selecting the degree of IOL in cataract patients with high myopia. Methods We collected the data of sex, age, axial length, predicted value of SRK/T, Haigis, Olsen formula and postoperative true diopter of 101eyes of 10z eyes hospitalized in the First Affiliated Hospital of Guangzhou University of Chinese Medicine from 2016-10-10 to 2019-8-20. 101 cases were divided into three groups according to the AL. The prediction accuracy of the three formulas for different eye axis length was evaluated respectively,and the stability of the same formula for the prediction of different axial lengths was compared. Results Within the range of 26mm0.05) and there was significant difference between Olsen formula with SRK/T formula and Olsen formula and Haigis formula(p 30mm, the comparison of the three formulas was statistically significant. SRK/T formula showed significant difference in eye axis length among the three groups(p<0.05). For Haigis formula, there was significant difference between 26mm30mm group respectively(P<0.05). In Olsen formula, the statistical difference only existed between 26mm
{"title":"Comparison of Three Intraocular Lens Calculation Formulas for Predicting Postoperative Diopter in Patients with Cataract and High Myopia","authors":"Ze-Peng Xu, Song-Tiao Li, Kun-Meng Li, Ruoxi Geng, Haike Guo, Hong-Yang Zhang, Haiyin Jin, AN Mei-Xia, N. Tian","doi":"10.35248/2155-9570.20.11.845","DOIUrl":"https://doi.org/10.35248/2155-9570.20.11.845","url":null,"abstract":"Objective: To evaluate the accuracy of three calculation formulas of intraocular lens (IOL) on the refractive state of cataract patients with high myopia after cataract surgery, to study the influence of three formulas on axial length (AL), and to verify the advantage of Olsen formula over SRK/T and Haigis formula in predicting postoperative refraction in patients with high myopia and cataract, so as to provide a basis for selecting the degree of IOL in cataract patients with high myopia, so as to provide a basis for selecting the degree of IOL in cataract patients with high myopia. Methods We collected the data of sex, age, axial length, predicted value of SRK/T, Haigis, Olsen formula and postoperative true diopter of 101eyes of 10z eyes hospitalized in the First Affiliated Hospital of Guangzhou University of Chinese Medicine from 2016-10-10 to 2019-8-20. 101 cases were divided into three groups according to the AL. The prediction accuracy of the three formulas for different eye axis length was evaluated respectively,and the stability of the same formula for the prediction of different axial lengths was compared. Results Within the range of 26mm0.05) and there was significant difference between Olsen formula with SRK/T formula and Olsen formula and Haigis formula(p 30mm, the comparison of the three formulas was statistically significant. SRK/T formula showed significant difference in eye axis length among the three groups(p<0.05). For Haigis formula, there was significant difference between 26mm30mm group respectively(P<0.05). In Olsen formula, the statistical difference only existed between 26mm","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"22 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77792820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.35248/2155-9570.20.11.830
M. M. Ali, Z. Hussein
Introduction: Hypertension is a common disease, which may be induced or precipitated by antivascular endothelial growth factor therapy with many studies reporting this complication of this therapy. Methods: This is a prospective study to evaluate blood pressure changes in normotensive, controlled and uncontrolled hypertensive patients on regular medical treatment after a 0.05 ml (0.5 mg) intravitreal Ranibizumab injection. It was held in Ibn-alhaitham eye teaching hospital in Baghdad between May 2019 and December 2019. It included patients with variable retinal diseases receiving either unilateral or bilateral intravitreal Ranibizumab injections, their blood pressure was measured before the treatment as a baseline, and then 2 hours, 1 month, and at 3 months from the first injection(s). These were allocated to three groups; Group A included normotensive patients without history of hypertension; Group B included controlled hypertensives and those with grade 1 hypertension with antihypertensive treatment. Group C included those with Grade 2 hypertension or more with antihypertensive treatment. Blood pressure was measured in all patients using the manual sphygmomanometer in sitting position. Paired t-test was used to analyze blood pressure measurements and compare mean arterial, systolic and diastolic pressure. A P-value of ≤ 0.05 was considered significant, and a P-value of ≤ 0.001 was considered highly significant. Results: Seventy-five patients (n=75) were included in the study with a mean age of 59.1 ± 11.4 years 58.7% males and 41.3% females, 44% were controlled-hypertensives, 26.7% were uncontrolled-hypertensives, 29.3% were normotensives. Group C showed highly significant reduction in the mean arterial, and systolic pressures in all three measurements after baseline (P ≤ 0.001), and significant reduction of diastolic blood pressure at one and three months after baseline (P ≤ 0.05). Both groups A and B showed a reduction in most measurements, but most were statistically insignificant (P ≥ 0.05). Unilateral and bilateral injection groups showed similar reduction in the mean arterial pressure at 2 hours and 3 months (P ≤ 0.05), mean systolic blood pressure was reduced in unilateral group in all 3 measurements (P ≤ 0.05, P ≤ 0.05, P ≤ 0.001, respectively) and also in the bilateral group at 2 hours and 3 months (P ≤ 0.001, P ≤ 0.05 respectively), and mean diastolic blood pressure was reduced at 2 hours in the unilateral group (P ≤ 0.05), and at 3 months in the bilateral injection group (P ≤ 0.05). Conclusion: There is an overall reduction of blood pressure with Ranibizumab Intravitreal injections especially in the moderate to severely uncontrolled hypertensive patients, while controlled-hypertensive, mildly uncontrolled hypertensive showed statistically insignificant changes which indicates that, it is acceptable to continue using Ranibizumab in both normotensive and hypertensive patients in the short
高血压是一种常见病，抗血管内皮生长因子治疗可能诱发或诱发高血压，许多研究报道了这种治疗的并发症。方法:这是一项前瞻性研究，评估正常、控制和未控制的高血压患者在接受常规药物治疗后，玻璃体内注射0.05 ml (0.5 mg)雷尼单抗后血压的变化。该活动于2019年5月至2019年12月在巴格达伊本-阿尔海瑟姆眼科教学医院举行。它包括接受单侧或双侧玻璃体内注射雷尼珠单抗的可变视网膜疾病患者，他们的血压在治疗前作为基线测量，然后在第一次注射后2小时、1个月和3个月测量。这些人被分成三组;A组为无高血压病史的正常血压患者;B组包括控制高血压患者和接受降压治疗的1级高血压患者。C组包括接受降压治疗的2级及以上高血压患者。所有患者均采用坐位手动血压计测量血压。采用配对t检验分析血压测量值，比较平均动脉压、收缩压和舒张压。p值≤0.05为显著，p值≤0.001为高度显著。结果:纳入研究的75例患者(n=75)，平均年龄59.1±11.4岁，男性占58.7%，女性占41.3%，高血压控制者占44%，高血压不控制者占26.7%，血压正常者占29.3%。C组在基线后三次测量的平均动脉压和收缩压均显著降低(P≤0.001)，在基线后1个月和3个月的舒张压均显著降低(P≤0.05)。A组和B组多数指标均有降低，但多数差异无统计学意义(P≥0.05)。单边和双边注射组显示出类似的降低平均动脉压在2小时,3个月(P≤0.05),意味着单边组收缩压降低在所有3测量(P≤0.05,P≤0.05,P≤0.001,分别),也在两国集团在2小时,3个月(分别P≤0.001,P≤0.05),和平均舒张压降低了在单边2小时组(P≤0.05),双侧注射组与3个月时比较(P≤0.05)。结论:雷尼单抗玻璃体腔内注射对血压有整体降低作用，特别是在高血压中度至重度不控制患者中，而高血压控制、轻度不控制患者的血压变化无统计学意义，提示短期内正常血压和高血压患者均可继续使用雷尼单抗。
{"title":"The Effect of Intravitreal Ranibizumab Injection on Systemic Blood Pressure: A Prospective Study","authors":"M. M. Ali, Z. Hussein","doi":"10.35248/2155-9570.20.11.830","DOIUrl":"https://doi.org/10.35248/2155-9570.20.11.830","url":null,"abstract":"Introduction: Hypertension is a common disease, which may be induced or precipitated by antivascular endothelial growth factor therapy with many studies reporting this complication of this therapy. Methods: This is a prospective study to evaluate blood pressure changes in normotensive, controlled and uncontrolled hypertensive patients on regular medical treatment after a 0.05 ml (0.5 mg) intravitreal Ranibizumab injection. It was held in Ibn-alhaitham eye teaching hospital in Baghdad between May 2019 and December 2019. It included patients with variable retinal diseases receiving either unilateral or bilateral intravitreal Ranibizumab injections, their blood pressure was measured before the treatment as a baseline, and then 2 hours, 1 month, and at 3 months from the first injection(s). These were allocated to three groups; Group A included normotensive patients without history of hypertension; Group B included controlled hypertensives and those with grade 1 hypertension with antihypertensive treatment. Group C included those with Grade 2 hypertension or more with antihypertensive treatment. Blood pressure was measured in all patients using the manual sphygmomanometer in sitting position. Paired t-test was used to analyze blood pressure measurements and compare mean arterial, systolic and diastolic pressure. A P-value of ≤ 0.05 was considered significant, and a P-value of ≤ 0.001 was considered highly significant. Results: Seventy-five patients (n=75) were included in the study with a mean age of 59.1 ± 11.4 years 58.7% males and 41.3% females, 44% were controlled-hypertensives, 26.7% were uncontrolled-hypertensives, 29.3% were normotensives. Group C showed highly significant reduction in the mean arterial, and systolic pressures in all three measurements after baseline (P ≤ 0.001), and significant reduction of diastolic blood pressure at one and three months after baseline (P ≤ 0.05). Both groups A and B showed a reduction in most measurements, but most were statistically insignificant (P ≥ 0.05). Unilateral and bilateral injection groups showed similar reduction in the mean arterial pressure at 2 hours and 3 months (P ≤ 0.05), mean systolic blood pressure was reduced in unilateral group in all 3 measurements (P ≤ 0.05, P ≤ 0.05, P ≤ 0.001, respectively) and also in the bilateral group at 2 hours and 3 months (P ≤ 0.001, P ≤ 0.05 respectively), and mean diastolic blood pressure was reduced at 2 hours in the unilateral group (P ≤ 0.05), and at 3 months in the bilateral injection group (P ≤ 0.05). Conclusion: There is an overall reduction of blood pressure with Ranibizumab Intravitreal injections especially in the moderate to severely uncontrolled hypertensive patients, while controlled-hypertensive, mildly uncontrolled hypertensive showed statistically insignificant changes which indicates that, it is acceptable to continue using Ranibizumab in both normotensive and hypertensive patients in the short ","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"55 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84919487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.35248/2155-9570.20.11.828
Tie Zhao
The Human Immunodeficiency Virus-1 (HIV-1) envelope protein gp120 is the major contributor to the pathogenesis of retinopathy and uveitis in HIV-1-related eye diseases. Disruption of the structure and function of the Blood-Retina Barrier (BRB) is the major contributor of HIV-1-related eye diseases and the molecular mechanism remains unknown. Our mini review revealed that retinopathy and uveitis are required for gp120- induced inflammation and epigenetic changes and suggest that gp120 regulate tight junction protein.
{"title":"HIV Associated Eye Diseases: Existing Cognitive and Possible Mechanisms","authors":"Tie Zhao","doi":"10.35248/2155-9570.20.11.828","DOIUrl":"https://doi.org/10.35248/2155-9570.20.11.828","url":null,"abstract":"The Human Immunodeficiency Virus-1 (HIV-1) envelope protein gp120 is the major contributor to the pathogenesis of retinopathy and uveitis in HIV-1-related eye diseases. Disruption of the structure and function of the Blood-Retina Barrier (BRB) is the major contributor of HIV-1-related eye diseases and the molecular mechanism remains unknown. Our mini review revealed that retinopathy and uveitis are required for gp120- induced inflammation and epigenetic changes and suggest that gp120 regulate tight junction protein.","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"3 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84300467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：